Azenta, Inc. 8K

Azenta, Inc. appointed director Dr. Martin Madaus as interim President and CEO following the resignation of John Marotta and reaffirmed its Q4 FY 2026 revenue guidance while noting a one-time $3 million consulting charge to adjusted EBITDA.

On August 24, 2026, Azenta, Inc. announced a leadership transition in which current director Dr. Martin Madaus was appointed interim President and CEO following the resignation of John Marotta as an executive officer and director, while the Board engaged Heidrick & Struggles to conduct a search for a permanent CEO. The company reaffirmed its previously issued fourth quarter fiscal 2026 total revenue guidance and disclosed that adjusted EBITDA for the quarter will be reduced by a one-time consulting expense of approximately $3 million, though excluding this charge the company would also reaffirm its adjusted EBITDA outlook. The announcement highlighted Dr. Madaus’s extensive prior CEO experience in diagnostics and life science tools and emphasized the Board’s confidence in his ability to ensure a smooth transition and continue execution of Azenta’s long-range strategic plan.

Filing Facts

CIK

933974

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-058519

Alert Tier

8